ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target Lowered to $5.00 at HC Wainwright

ImmunoPrecise Antibodies (NASDAQ:IPA) had its target price reduced by HC Wainwright from $7.00 to $5.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the stock.

ImmunoPrecise Antibodies Stock Performance

NASDAQ:IPA opened at $0.38 on Monday. The company has a 50-day moving average of $0.43 and a 200-day moving average of $0.47. The firm has a market cap of $11.69 million, a price-to-earnings ratio of -0.48 and a beta of 0.09. The company has a current ratio of 1.01, a quick ratio of 0.85 and a debt-to-equity ratio of 0.36. ImmunoPrecise Antibodies has a twelve month low of $0.27 and a twelve month high of $1.59.

ImmunoPrecise Antibodies (NASDAQ:IPA) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. The firm had revenue of $4.23 million for the quarter, compared to analyst estimates of $6.59 million. Analysts forecast that ImmunoPrecise Antibodies will post -0.27 earnings per share for the current fiscal year.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC lifted its position in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,558,892 shares of the company’s stock after acquiring an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned approximately 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the SEC. 6.70% of the stock is owned by institutional investors.

ImmunoPrecise Antibodies Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.